BACKGROUND/AIM: In prostate cancer, postoperative radiotherapy timing is debated to avoid overtreatments and toxicities. This study compared acute and late rectal and bladder toxicities in the adjuvant and salvage setting. PATIENTS AND METHODS: In total, 129 patients were analyzed in two groups: adjuvant radiotherapy (aRT) and salvage radiotherapy (sRT). RESULTS: In aRT and sRT, grade 1 (G1) acute bladder toxicities were detected in 40 and 30 patients, and grade 2 (G2) in 1 and 6; G1 late bladder toxicities were described in 30 and 20, and G2 in 6 and 2, respectively. In aRT and sRT, acute G1 rectal toxicities were reported in 18 and 27 patients, and G2 in 5 and 4, respectively. Late rectal G1 toxicities were observed in 10 patients, G2 in 6 and G3 in 1 in the aRT. In sRT, 8 patients and 1 developed G1 and G2 toxicities, respectively. Regarding bladder toxicity, a higher incidence occurred in aRT; late toxicity was lower in sRT. CONCLUSION: Adjuvant and salvage RT in prostate cancer treatment resulted in acceptable toxicities.
BACKGROUND/AIM: In prostate cancer, postoperative radiotherapy timing is debated to avoid overtreatments and toxicities. This study compared acute and late rectal and bladder toxicities in the adjuvant and salvage setting. PATIENTS AND METHODS: In total, 129 patients were analyzed in two groups: adjuvant radiotherapy (aRT) and salvage radiotherapy (sRT). RESULTS: In aRT and sRT, grade 1 (G1) acute bladder toxicities were detected in 40 and 30 patients, and grade 2 (G2) in 1 and 6; G1 late bladder toxicities were described in 30 and 20, and G2 in 6 and 2, respectively. In aRT and sRT, acute G1 rectal toxicities were reported in 18 and 27 patients, and G2 in 5 and 4, respectively. Late rectal G1 toxicities were observed in 10 patients, G2 in 6 and G3 in 1 in the aRT. In sRT, 8 patients and 1 developed G1 and G2 toxicities, respectively. Regarding bladder toxicity, a higher incidence occurred in aRT; late toxicity was lower in sRT. CONCLUSION: Adjuvant and salvage RT in prostate cancer treatment resulted in acceptable toxicities.
Authors: Sameer K Nath; Ajay P Sandhu; Brent S Rose; Daniel R Simpson; Polly D Nobiensky; Jia-Zhu Wang; Fred Millard; Christopher J Kane; J Kellogg Parsons; Arno J Mundt Journal: Int J Radiat Oncol Biol Phys Date: 2009-11-24 Impact factor: 7.038
Authors: Jeff M Michalski; Colleen Lawton; Issam El Naqa; Mark Ritter; Elizabeth O'Meara; Michael J Seider; W Robert Lee; Seth A Rosenthal; Thomas Pisansky; Charles Catton; Richard K Valicenti; Anthony L Zietman; Walter R Bosch; Howard Sandler; Mark K Buyyounouski; Cynthia Ménard Journal: Int J Radiat Oncol Biol Phys Date: 2009-04-23 Impact factor: 7.038
Authors: Thomas Wiegel; Dirk Bottke; Ursula Steiner; Alessandra Siegmann; Reinhard Golz; Stephan Störkel; Norman Willich; Axel Semjonow; Rainer Souchon; Michael Stöckle; Christian Rübe; Lothar Weissbach; Peter Althaus; Udo Rebmann; Tilman Kälble; Horst Jürgen Feldmann; Manfred Wirth; Axel Hinke; Wolfgang Hinkelbein; Kurt Miller Journal: J Clin Oncol Date: 2009-05-11 Impact factor: 44.544
Authors: Ian M Thompson; Catherine M Tangen; Jorge Paradelo; M Scott Lucia; Gary Miller; Dean Troyer; Edward Messing; Jeffrey Forman; Joseph Chin; Gregory Swanson; Edith Canby-Hagino; E David Crawford Journal: J Urol Date: 2009-01-23 Impact factor: 7.450
Authors: Paul Sargos; Sylvie Chabaud; Igor Latorzeff; Nicolas Magné; Ahmed Benyoucef; Stéphane Supiot; David Pasquier; Menouar Samir Abdiche; Olivier Gilliot; Pierre Graff-Cailleaud; Marlon Silva; Philippe Bergerot; Pierre Baumann; Yazid Belkacemi; David Azria; Meryem Brihoum; Michel Soulié; Pierre Richaud Journal: Lancet Oncol Date: 2020-10 Impact factor: 41.316
Authors: Claire L Vale; David Fisher; Andrew Kneebone; Christopher Parker; Maria Pearse; Pierre Richaud; Paul Sargos; Matthew R Sydes; Christopher Brawley; Meryem Brihoum; Chris Brown; Sylvie Chabaud; Adrian Cook; Silvia Forcat; Carol Fraser-Browne; Igor Latorzeff; Mahesh K B Parmar; Jayne F Tierney Journal: Lancet Date: 2020-09-28 Impact factor: 79.321
Authors: Andrew Kneebone; Carol Fraser-Browne; Gillian M Duchesne; Richard Fisher; Mark Frydenberg; Alan Herschtal; Scott G Williams; Chris Brown; Warick Delprado; Annette Haworth; David J Joseph; Jarad M Martin; John H L Matthews; Jeremy L Millar; Mark Sidhom; Nigel Spry; Colin I Tang; Sandra Turner; Kirsty L Wiltshire; Henry H Woo; Ian D Davis; Tee S Lim; Maria Pearse Journal: Lancet Oncol Date: 2020-10 Impact factor: 41.316